-

Shareholder Alert: Robbins LLP Announces It Is Investigating Expedia Group, Inc. (EXPE) On Behalf of former Liberty Expedia Holdings, Inc. (LEXEA, LEXEB) Shareholders

SAN DIEGO & SEATTLE--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of Expedia Group, Inc. (NASDAQ: EXPE) potentially violated federal securities laws in connection with its June 2019 merger and acquisition of Liberty Expedia Holdings (NASDAQ: LEXEA, LEXEB). Expedia Group, Inc. is an online travel company that operates worldwide.

If you suffered a loss due to Expedia Group's misconduct, click here.

Expedia Group, Inc. (EXPE) Merger with Liberty Expedia Holdings (LEXEA, LEXEB) Harmed Investors

In June 2019, Expedia acquired Liberty Expedia in an all-stock transaction. Under the terms of agreement, Expedia issued 0.360 shares of Expedia common stock to each former holder of Liberty Expedia series A common stock and series B common stock. At the time of the merger, Expedia’s SEC filings failed to disclose material information and negative trends that were already adversely impacting Expedia’s business. When Expedia disclosed the impact of these adverse trends after the merger, Expedia's stock price plummeted causing former Liberty shareholders to suffer severe losses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Expedia Group settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom